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Abstract We have recently found that ralGDS family members 
(RGL and ralGDS) are putative effector proteins of ras p21. rapl 
p21 is a small GTP-binding protein which has the same amino 
acid sequence as the effector loop of ras p21. We examined the 
effect of rapl p21 on the interaction of ras p21 with RGL. The 
GTP-bound form of rapl p21 interacted with RGL as well as did 
ras p21. rapl p21 inhibited the interaction of ras p21 with RGL. 
RGL was phosphorylated by cyclic AMP-dependent protein ki- 
nase (protein kinase A). Phosphorylation of RGL did not affect 
its binding to ras p21 and rapl p21 under the conditions that 
phosphorylation of Raf-1 reduced its affinity for ras p21. These 
results demonstrate that rapl p21 but not protein kinase A regu- 
lates the interaction of ras p21 with RGL and suggest hat rapl 
p21 and protein kinase A may cooperate to distinguish the signal 
of ras p21 to RGL from that to Raf-1. 
Key words: rapl p21; ras p21; RGL; ralGDS; Protein kinase A; 
Raf-1 
1. Introduction 
ras p21 is a member of small G protein superfamily and is 
important for cell growth and differentiation [1 6]. Several mu- 
tations of ras p21 have been found in human cancers uch as 
colon cancer and pancreatic ancer [1,3]. To identify effector 
protein(s) which directly interacts with the active form of ras 
p21 and exerts biological effects has been a major goal of 
research of ras  p21 to clarify the mode of action ofras  p21. The 
interaction of ras p21 with effector protein(s) requires the effec- 
tor loop of ras p21 (amino acids 3240) [1,3]. The effector 
protein(s) of ras p21 has some activity that is regulated by its 
interaction with the active form of ras p21, and this activity is 
responsible for some of biological effect of ras p21 in the cells. 
Raf-I is a serine/threonine kinase and is identified to be an 
effector protein which mediates a ras p21-dependent signal 
[5-13]. Raf-I phosphorylates and activates MEK and in turn 
activates MAPK. This pathway mediates the signal into the 
nuclei, leading to activation of primary-response nuclear proto- 
oncogenes uch as c-fos and c-myc by phosphorylation [5,6]. 
However, it is possible that ras p21 has effector proteins other 
than Raf-1, since ras p21 possesses multiple functions, pl20- 
GAP, p110 subunit of PI3-kinase, and MEKK are possible 
effector proteins of ras p21 in that these proteins interact with 
the GTP-bound form of ras p21 and that these proteins have 
an influence downstream of ras p21 in various signaling path- 
way [14-17]. However, several evidence has suggested that 
pl20-GAP and p110 subunit of PI3-kinase act as regulators of 
ras p21 [18,19]. Whether GAP or PI3-kinase is an effector 
protein of ras p21 might depend on cell types. 
We have identified RGL (ralGDS like) as a new effector 
protein of ras p21 [20]. RGL has 70% amino acid homology 
with ralGDS [21]. The C-terminal domain of RGL and ralGDS 
has been found to associate with the GTP-bound form of ras 
p21 through the effector loop of ras p21 [20,22,23]. ralGDS 
stimulates GDP/GTP exchange of ral p24 [21]. ral p24 has been 
originally isolated by probing with an oligonucleotide corre- 
sponding to one of the GTP-binding domain of ras p21 [24]. 
Although the function of ral p24 is not yet understood, ralGDS 
and RGL may regulate the signal from ras p21 to ral p24. 
rapl p21 is a member of small G protein superfamily [25,26]. 
rapl p21 shares 55% amino acid identity with ras p21 and rapl 
p21 has the same amino acid sequence as the effector loop of 
ras p21 [25,26]. Therefore, it is conceivable that rapl p21 exerts 
actions antagonistic or similar to those of ras p21. Indeed, rapl 
p21 antagonizes ras p21 functions in several cells [25-30]. rapl 
p21 has been shown to interact with Raf-1 by the yeast two 
hybrid system [8]. Recently the crystal structure of the complex 
between Raf-1 and rapl p21 has been solved and it has been 
shown that the interaction of these proteins occurs between 
residues of the anti-parallel fl-sheets formed from two fl-sheets 
of the effector loop of rapl p21 and two fl-sheets of the ras 
p21-binding domain of Raf-1 [31]. These results strongly sug- 
gest that the biological effects of rapl p21 are results of compe- 
tition with ras p21 for the effector proteins of ras p21 and 
prompted us to examine whether ap 1 p21 regulates the interac- 
tion of ras p21 with RGL. In this paper we show that rapl p21 
binds directly to RGL, a new effector protein of ras p21, and 
that rapl p21 inhibits the binding of ras p21 to RGL. 
2. Materials and methods 
*Corresponding author. Fax: (81) (82) 257-5134. 
Abbreviations." G protein, GTP-binding protein; MEK, MAPK and 
ERK kinase; MAPK, mitogen-activated protein kinase; MEKK, MEK 
kinase; GAP, GTPase activating protein; PI3-kinase, phosphatidylinos- 
itol 3-kinase; RGL, RalGDS like; protein kinase A, cyclic AMP-de- 
pendent protein kinase, GTP~'S, guanosine 5'-(3-O-thio)triphosphate; 
RID, ras p21-interacting domain; PCR, polymerase chain reaction; 
GST, glutathione-S-transferase; MBP, maltose-binding protein; DTT, 
dithiothreitol. 
2.1. Materials" and chemicals 
The RGL cDNA was provided by Drs. Z. Ye and L.T. Willimas 
(Chiron Corp., USA). The c-H-ras p21, raplA p21, racl p21, and ralB 
p24 cDNAs were provided by Drs. J. Downward (Imperial Cancer 
Research Institute, UK), C. Der (The University of North Carolina, 
USA), A. Hall (Imperial Cancer Research Institute, UK), and R. Wein- 
berg (Whitehead Institute for Biomedical Research, USA), respectively. 
pMAL/Raf(1 257) was kindly supplied from Dr. T. Kataoka (Kobe 
University, Japan) [32]. The catalytic subunit of protein kinase A was 
from Dr. M. Inagaki (Tokyo Metropolitan I stitute of Gerontology, 
0014-5793195l$9.50 © 1995 Federation of European Biochemical Societies. All rights reserved. 
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Japan). pMAL-c was purchased from New England Biolabs. 
[35S]GTPyS and [3H]GDP were from DuPont NEN Research Pro- 
ducts. 
2.2. Plasmid constructions 
The amino acids 602-768 of RGL contained RID [20]. pMAL/RID 
(pMAL/RGL(602-768)) was constructed by the following procedures. 
The oligonucleotide corresponding tothe Myc epitope was synthesized 
by PCR. This oligonucleotide was designed to have the EcoRI site at 
the 5' end and the BamHI site at the 3' end. pBSKS/RID [20] was 
digested with XhoI and EeoRI. RID and the Myc epitope were ligated 
with pGEM7z which was digested with XhoI and BamHI to generate 
pGEM7z/RID, pMAL-c was digested with PstI and the protruding 3' 
overhang was removed by T4 DNA polymerase, pGEM7z/RID was 
digested with ShpI and SacI to obtain the RID-Myc fragment. This 
fragment was treated with T4 DNA polymerase, pMAL-c and the 
RID-Myc fragment were ligated to generate pMAL/RID. To construct 
pGEX-2T encoding H-ras p21, raplA p21, racl p21, and ralB p24, 0.6 
kb fragments containing these small G proteins with BamHI and EcoRI 
sites were synthesized by PCR. These fragments were digested with 
BamHI and EcoRI and inserted into the BamHI and EcoRI cut pGEX- 
2T to generate pGEX/H-ras p21, pGEX/raplA p21, pGEX/racl p21, 
and pGEX/ra/B p24. 
2.3. Expression and purification of GST-fused to small G proteins and 
MBP-fused to RID and Raf(1-257) 
Transformed Escherichia coli were initially grown at 37°C to an 
absorbance of 0.8 (optical density at 600 nm) and subsequently trans- 
ferred to 25°C. Then isopropyl-l-,8-o-galactopyranoside was added at 
a final concentration f0.1 mM and further incubation was carried out 
for 10 h at 25°C. The GST- and MBP-fused to proteins were purified 
by affinity chromatographies n accordance with the manufacturer's 
instructions. In the guanosine nucleotide-binding assay described 
below, about 0.3 mol of GTPyS or GDP bound to 1 mol of GST-fused 
to small G proteins. We do not know the exact reasons for the low 
stoichiometry of the guanosine nucleotide-binding to these small G 
proteins. 
2.4. Binding assay of small G proteins and RID or Raf(1-257) 
To make immobilized RID or Raf(1-257) on amylose resin, 500/.tg 
of MBP-RID or 250 #g of MBP-Raf(l~57) was incubated with 200/A 
of amylose resin in 500//1 of reaction mixture (20 mM Tris-HC1 [pH7.5], 
1 mM DTT, and 200 mM NaC1) for 2 h at 4°C. The resin was precip- 
itated by centrifugation and washed with 10 mM Tris-HC1 (pH 7.5) 
three times. One/,tl of aliquot of the resin bound to 20 pmol of MBP- 
RID or 2.2 pmol of MBP-Raf(1-257). To make the [35S]GTPzS- or 
[3H]GDP-bound form of small G proteins, each of small G proteins (10 
pmol) was incubated with 2/IM [35S]GTPzS (10,000-20,000 cpm/pmol) 
or 2/~M [3H]GDP (40,000-60,000 cpm/pmol) for 10 min at 30°C in 40 
/11 of reaction mixture (50 mM Tris-HC1 (pH 7.5), 10 mM EDTA, 5 mM 
MgC12, and 1 mM DTT). After the incubation, 1M MgC12 was added 
at a final concentration f 20 mM. The [3~S]GTPyS- or [3H]GDP-bound 
form of small G proteins were incubated for 30 min at 4°C with 
immobilized RID or Raf(1 257) (15 pmol) in 100/.tlofreactionmixture 
(50 mM Tris-HC1 (pH 7.5), 10 mM EDTA, 20 mM MgC12, 1 mM DTT, 
and 10 pM GTPzS or 10/.tM GDP). Immobilized RID and Raf(1-257) 
were precipitated by centrifugation, the precipitated resin was washed, 
and the remaining radioactivities were counted. During the procedures 
of this assay, neither [35S]GTPzS nor [3H]GDP dissociated from 
[35S]GTP~,S- or [3H]GDP-bound form of small G proteins. 
2.5. Phosphorylation fRID and Raf-1 by protein kinase A 
Immobilized RID and Raf(1-257) (15 pmol each) were incubated 
with the catalytic subunit of protein kinase A (500 ng of protein) for 
30 min at 30°C in 30/11 of reaction mixture (50 mM Tris-HC1 (pH 7.5), 
10 mM MgCI2, 1 mM DTT, and 25/~M ATP). Under these condi- 
tions 0.8 mol of phosphate was incorporated into 1 mol of RID and 
Raf(1-257). 
3. Results 
3.1. Specificity of the interaction of small G proteins with RGL 
We have previously found that the amino acid 602-768 of 
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Fig. 1. Specificity of the interaction of small G proteins to RGL. The 
[35S]GTP~'S- (lanes 1, 3, 5, and 7) or [3H]GDP- (lanes 2, 4, 6, and 8) 
bound form of rapl p21 (lanes 1 and 2), ras p21 (lanes 3 and 4), rael 
p21 (lanes 5 and 6), and ral p24 (lanes 7 and 8) (10 pmol each) were 
incubated with immobilized RID (15 pmol). The radioactivities of the 
resin were counted. The results hown are representative of three inde- 
pendent experiments. 
RGL  is a ras p21-interacting domain (RID) by the yeast two- 
hybrid system [20]. We first examined the direct binding of 
small G proteins such as ras p21, rapl p21, racl p21 or ral p24 
to R ID using the purified proteins. Both the GTPzS-bound 
form of ras p21 and rapl p21 associated with RID, but neither 
the GTPTS-bound form of racl p21 nor ra! p24 bound to R ID 
(Fig. 1). None of the GDP-bound form of ras p21, rapl p21, 
racl p21 or ral p24 associated with R ID  (Fig. 1). These results 
show that rapl p21 and ras p21 which have the same effector 
loop bind directly to R ID  of RGL  in their GTP-bound active 
form. 
3.2. Affinity ofrapl p21 for RGL 
Both the GTPzS-bound form of rapl p21 and ras p21 inter- 
acted with R ID  in a dose-dependent manner (Fig. 2A). The 
maximal binding activity of rapl p21 to R ID  was almost the 
same as that ofras p21 to RID. The affinity ofrapl p21 for R ID 
was higher than that ofras p21 for RID. The K d values ofrapl 
p21 and ras p21 for R ID were estimated to be 10 nM and 80 
nM, respectively, by Scatchard plot analysis. 
3.3. Inhibition of the interaction ofras p21 with RGL by rap/ 
p21 
rapl p21 has the same amino acid sequence as the effector 
loop of ras p21. Since the effector proteins of ras p21 interact 
with ras p21 through its effector loop, ideally rapl p21 should 
inhibit the interaction of ras p21 with its effector proteins. We 
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examined this possibility. As expected, rap1 p21 inhibited the 
binding of ras p21 to RID in a dose-dependent manner (Fig. 
2B). The concentration of rapl p21 required to inhibit 50% of 
the interaction of ras p21 with RID was 25 nM. The concentra- 
tion of ras p21 used in this experiment was 200 nM. Therefore, 
these results indicate that the affinity of rapl p21 for RGL is 
8-fold higher than that of ras p21 for RGL and are consistent 
with the results in Fig. 2A. 
3.4. Effect of  the phosphorylation of  RID by protein kinase A on 
the interaction ofras p21 and rapl p21 with RID 
It has been known that Raf-1 is phosphorylated by protein 
kinase A and that phosphorylation f Raf-1 reduces the bind- 
ing of Raf- 1 to ras p21 [33,34]. Therefore, we examined whether 
protein kinase A affects the interaction of RGL with ras p21 
and rapl p21. RID was phosphorylated by protein kinase A 
and 0.8 mol of phosphate was incorporated into 1 mol of RID 
(data not shown). The phosphorylation f RID did not affect 
its interaction with rapl p21 or ras p21 (Fig. 3, lanes 1-4) 
although that of Raf(1-257) by protein kinase A reduced its 
binding to ras p21 (Fig. 3, lanes 5 and 6). These results uggest 
that protein kinase A does not regulate the interaction of rapl 
p21 or ras p21 with RGL although protein kinase A inhibits 
the interaction of ras p21 with Raf-1. 
4. D iscuss ion  
We have shown here that rapl p21 directly binds to RGL 
with a high affinity as well as does ras p21 and that rapl p21 
inhibits the interaction ofras p21 with RGL. rapl p21 is known 
to antagonize the signal of ras p21 to lead to gene induction and 
cell growth through the Raf/MAPK pathway in various cells 
[25-30]. Since rapl p21 has the same amino acid sequence as 
the effector loop ofras p21 and interacts with Raf-1 [25,26,31], 
it is possible that rapl p21 inhibits the binding of ras p21 to 
Raf-1 by competing with the effector loop of ras p21. By anal- 
ogy with this inhibitory mechanism, rap 1 p21 might inhibit the 
binding of ras p21 to RGL by competing with the effector loop 
of ras p21. Since RGL is a member of ralGDS family and has 
_~15 A 
E 
GTP'/S-bourtd form of ras or rap (nM) 
I00 200 
GTl~/S-b~und form of rap (riM) 
Fig. 2. (A) Affinity of rapl p21 and ras p21 for RGL. The indicated 
concentrations of [35S]GTPyS-bound form of rap1 p21 (o) and ras p21 
(o) were incubated with immobilized RID (15 pmol). The radioactivi- 
ties of the resin were counted. (B) Inhibition of the interaction of ras 
p21 with RGL by rapl p21. The [35S]GTPyS-bound form ofras p21 (20 
pmol) was incubated with immobilized RID (15 pmol) in the presence 
of the indicated concentrations of the GTP~,S-bound form of rap 1 p21. 
The radioactivities of the resin were counted. The results shown are 
representative of three independent experiments. 
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Fig. 3. Effect of the phosphorylation f RGL by protein kinase A on 
the interaction of RGL with rapl p21 and ras p21. The [35S]GTPyS- 
bound form of rapl p21 was incubated with the unphosphorylated or 
phosphorylated form of immobilized RID (lanes 1 and 2). The 
[35S]GTPTS-bound form of ras p21 was incubated with the un- 
phosphorylated or phosphorylated form of immobilized RID (lanes 3 
and 4). The [35S]GTPyS-bound form of ras p21 was incubated with the 
unphosphorylated or phosphorylated form of immobilized Raf(1-257) 
(lanes 5 and 6). The radioactivities of the resin were counted. The 
binding activity of rapl p21 or ras p21 to RID or Raf(1-257) was 
expressed as percentage of that without protein kinase A treatment 
(lanes 1, 3, and 5). PKA, protein kinase A. The results shown are 
representative of three independent experiments. 
a GDP/GTP exchange activity of ral p241, RGL may mediate 
the signal from ras p21 to ral p24. Our results uggest that rapl 
p21 regulates the signal from ras p21 to ral p24 through RGL 
(RalGDS) in addition to the action antagonistic to ras p21/Raf/ 
MAPK pathway. 
We have also found that phosphorylation f RID by protein 
kinase A does not affect the interaction of rapl p21 or ras p21 
with RID. In RID, RKKNS 735 is a consensus equence of the 
phosphorylation by protein kinase A. Although 5 735 could be 
phosphorylated by protein kinase A, the physiological signifi- 
cance of the phosphorylation f RID is not known. In contrast, 
the phosphorylation f Raf-I by protein kinase A reduced its 
binding to ras p21 [33,34]. The decrease of the affinity of Raf-1 
for ras p21 by protein kinase A might be one of the mechanism 
by which the signals through cyclic AMP inhibit the prolifera- 
tion of the cells [35]. Taken together with the previous observa- 
tions, rapl p21 and protein kinase A inhibit the signal from ras 
p21 to Raf-1, while rapl p21 but not protein kinase A inhibits 
the signal from ras p21 to RGL. Therefore, it is conceivable 
that rapl p21 and protein kinase A are important for ras p21 
to distinguish two different effector proteins. 
We have previously found that rapl p21 stimulates DNA 
synthesis as well as ras p21 in Swiss 3T3 cells [36]. These results 
indicate that rapl p21 exerts its own action depending on cell 
types. Although both rapl p21 and ras p21 are ubiquitously 
detected in various tissues, rapl p21 shows tissue and subcellu- 
Akira Kikuchi and Lewis T. Williams, unpublished observations, 
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lar distributions partly distinct from those of ras p21 [25,26]. 
The amount of rapl p21 is at least ten times higher than that 
of ras p21 in bovine aortic smooth muscle, rat heart, and human 
platelets. In the synapse of rat brain, rapl p21 is found in the 
synaptic plasma membrane, the synaptic vesicle, and the synap- 
tic mitochondria, while ras p21 is primarily located to the syn- 
aptic plasma membrane. Since ralGDS is ubiquitously ex- 
pressed in various tissues [21], rapl p21 may exert its own 
specific actions through RGL (ralGDS) in places where rapl 
p21 alone is expressed. Taken together with the observations 
that ral p24 is localized to the synaptic vesicle [37], it is intrigu- 
ing to speculate that the signal from rap 1 p21 to ral p24 through 
RGL (ralGDS) is important for the function of the synaptic 
vesicle. 
Recently, ralBP1 has been found to be a putative effector 
protein ofral p24 [38]. ralBP1 has a GTPase stimulating activity 
for CDC42 and rac p21. CDC42 and rac p21 are known to 
regulate the assembly of multimolecular focal complexes at the 
plasma membrane [39]. Therefore, RGL(ra lGDS) might be a 
key protein to mediate cross talk between ras p21, rapl p21, ral 
p24, CDC42, and rac p21. Further studies are necessary for 
understanding this new signal transduction pathway of ras p21 
which regulates the action of ra! p24. 
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